Weight Loss

Retatrutide

Triple agonist

Next-generation triple agonist (in late trials 2026).

⚡ Fat Loss

Mechanism of Action

GLP-1 + GIP + glucagon agonism.

Key Benefits

Up to 24%+ weight loss in trials

Common Uses

Severe obesity (pending approval)

What to Expect

Onset

Appetite suppression within 24–48 hours; described as the strongest onset in the GLP-1 class

Duration

~7 days per injection; triple mechanism provides powerful and sustained metabolic effects

What Users Report

Very strong appetite suppression — consistently described as the most potent of all GLP-1 class drugs
Rapid and dramatic weight loss exceeding what semaglutide or tirzepatide achieve
GI side effects similar to other GLP-1s but can be more pronounced, especially at higher doses
Feeling of increased energy expenditure — some report feeling warmer and having higher metabolic rate
The glucagon component appears to help preserve lean mass better than GLP-1-only drugs
Early clinical data shows up to 24%+ total body weight loss — the most of any weight loss drug tested
Still in trials — user reports are limited to clinical trial participants, but results are exceptional

Typical Timeline

Days 1–2: Strong appetite suppression onset. Weeks 1–4: Titration phase — managing GI effects while dose increases. Weeks 4–12: Accelerated weight loss; often faster than other GLP-1 agents. Months 3–12: Clinical trial data shows 24%+ total weight loss at 48 weeks. Note: Pending FDA approval; available primarily through clinical trials.